← Human Trials & Peer-Reviewed Studies
Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study
Plain-language guide to PMID 12738624 (2003): double-blind randomized controlled trial study of BNP (Nesiritide) in 12 subjects.
Key Facts
- PMID
- 12738624
- Journal
- American journal of physiology. Heart and circulatory physiology
- Year
- 2003
- Study type
- Randomized Controlled Trial
- Authors
- van der Zander K et al. (5 authors)
- DOI
- 10.1152/ajpheart.00085.2003
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.
The aim of this study was to investigate the cardiovascular effects of pathophysiological levels of BNP on central hemodynamics, cardiac function, renal hemodynamics and function, and microvascular hemodynamics in healthy subjects.
Why It Was Studied
Brain natriuretic peptide (BNP) is a cardiac hormone with natriuretic activity.
Blood pressure and heart rate were monitored for all measurements.
Who Took Part
The study group was 12 subjects.
The age groups tagged for this paper are middle-aged adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
The subjects were allocated by chance, so the BNP (Nesiritide) group and the comparison group should start out alike.
As a double-blind BNP (Nesiritide) study, the assignments were hidden from both participants and investigators until the end.
Some subjects received a placebo instead of BNP (Nesiritide), giving a reference point.
In the crossover set-up each of the subjects took both BNP (Nesiritide) and the comparison in turn, acting as their own control.
What Was Measured
Blood pressure and heart rate were monitored for all measurements.
Topics PubMed links to this paper include Blood Pressure, Conjunctiva, Cyclic GMP, Diuresis, Heart Rate, Kidney and Microcirculation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of BNP (Nesiritide) in 12 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2003 (American journal of physiology. Heart and circulatory physiology), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.